RESEARCH TRIANGLE PARK, N.C. – October 21, 2003 – Quintiles Transnational Corp. today announced an agreement with the Peking Union Medical College Hospital (PUMCH) in Beijing to expand Quintiles' central laboratory services in China.
The agreement permits Quintiles to use laboratory-testing services within PUMCH's extensive clinical laboratory. PUMCH is one of China's premier academic institutions and a leader in clinical research. Quintiles Laboratories will place staff within PUMCH to provide support services associated with the collection and management of clinical trial specimens for Quintiles' customers. Other laboratory services in support of investigators in China and project management will be provided by Quintiles' facilities in Singapore.
China closely regulates the export of whole blood, including clinical trial samples. With access to the PUMCH laboratories, Quintiles can help customers save valuable time during the clinical trial process.
Neil Ferguson, Managing Director, Quintiles Greater China, said: "We are very excited about the expansion of our global services. China is an excellent country for clinical research, offering rapid patient recruitment, large patient populations and unique gene pools. We are delighted to be working with such a reputable laboratory and hospital in China. With this agreement, we intend to offer our customers access to a large number of new investigators and patients while effectively managing time requirements and maintaining our consistent high global standards."
Founded in 1921, PUMCH has 1,200 beds, 2,480 employees and more than 400 professors. The hospital supports 3,500 outpatient visits a day and 25,000 inpatient visits a year.
"We are very happy to cooperate with Quintiles, the leading global CRO," said Dr. Qi Kemin, PUMCH Director. "We hope to work together with Quintiles to expand clinical research in China."
Dr. Ni Anping, director of clinical laboratories for PUMCH, said, "PUMCH already has experience working on global trials, and we hope that through our alliance with Quintiles we will have many more opportunities to participate in international clinical research."
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, and with offices in more than 40 countries, Quintiles is a leading global pharmaceutical services organization and a member of the Fortune 1000. For more information visit the company's Web site at www.quintiles.com.
About Quintiles Laboratories
Quintiles Laboratories is a global, full-service organization that provides analytical testing and data management services to meet the needs of Phase I through Phase IV clinical trials. Quintiles Laboratories has central laboratory services in Atlanta, Ga.; Livingston, Scotland; Singapore; and Pretoria, South Africa, and has a partner laboratory network in Australia and South America.
This press release contains forward-looking statements regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially. The risks and uncertainties with respect to Quintiles include, without limitation, the risk that the market for Quintiles' products and services will not grow as expected, the risk that Quintiles will not be able to effectively manage time requirements or maintain consistent high global standards with respect to its operations in China, actual operating performance, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to the company's Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.